Nilotinib-loaded gelatin methacryloyl microneedles patch for the treatment of cardiac dysfunction after myocardial infarction.
10.7507/1001-5515.202208039
- Author:
Ningxin PENG
1
;
Jun XIE
1
Author Information
1. Department of Cardiology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, P. R. China.
- Publication Type:Journal Article
- Keywords:
Cardiac dysfunction;
Gelatin methacryloyl;
Microneedles patch;
Myocardial infarction;
Nilotinib
- MeSH:
Humans;
Myocardial Infarction/drug therapy*;
Cardiomegaly;
Natriuretic Peptide, Brain/therapeutic use*;
Fibrosis;
Myocardium/pathology*
- From:
Journal of Biomedical Engineering
2023;40(5):996-1004
- CountryChina
- Language:Chinese
-
Abstract:
The study aimed to evaluate the therapeutic effect of nilotinib-loaded biocompatible gelatin methacryloyl (GelMA) microneedles patch on cardiac dysfunction after myocardial infarction(MI), and provide a new clinical perspective of myocardial fibrosis therapies. The GelMA microneedles patches were attached to the epicardial surface of the infarct and peri-infarct zone in order to deliver the anti-fibrosis drug nilotinib on the 10th day after MI, when the scar had matured. Cardiac function and left ventricular remodeling were assessed by such as echocardiography, BNP (brain natriuretic peptide) and the heart weight/body weight ratio (HW/BW). Myocardial hypertrophy and fibrosis were examined by WGA (wheat germ agglutinin) staining, HE (hematoxylin-eosin staining) staining and Sirius Red staining. The results showed that the nilotinib-loaded microneedles patch could effectively attenuate fibrosis expansion in the peri-infarct zone and myocardial hypertrophy, prevent adverse ventricular remodeling and finally improve cardiac function. This treatment strategy is a beneficial attempt to correct the cardiac dysfunction after myocardial infarction, which is expected to become a new strategy to correct the cardiac dysfunction after MI. This is of great clinical significance for improving the long-term prognosis of MI patients.
